



Commentary

Imaging the high-affinity state of the dopamine D₂ receptor in vivo: Fact or fiction?Mette Skinbjerg^{a,b,*}, David R. Sibley^c, Jonathan A. Javitch^{a,c,d}, Anissa Abi-Dargham^{a,b}^a Department of Psychiatry, Columbia University, New York, NY, USA^b Department of Translational Imaging, New York State Psychiatric Institute, New York, NY, USA^c Center for Molecular Recognition, Columbia University, New York, NY, USA^d Department of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY, USA^e Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA

ARTICLE INFO

Article history:

Received 10 August 2011

Accepted 8 September 2011

Available online 16 September 2011

Keywords:

D₂ receptor

High-affinity state

Agonist binding

PET imaging

ABSTRACT

Positron Emission Tomography (PET) has been used for more than three decades to image and quantify dopamine D₂ receptors (D₂R) in vivo with antagonist radioligands but in the recent years agonist radioligands have also been employed. In vitro competition studies have demonstrated that agonists bind to both a high and a low-affinity state of the D₂Rs, of which the high affinity state reflects receptors that are coupled to G-proteins and the low-affinity state reflects receptors uncoupled from G-proteins. In contrast, antagonists bind with uniform affinity to the total pool of receptors. Results of these studies led to the proposal that D₂Rs exist in high and low-affinity states for agonists in vivo and sparked the development and use of agonist radioligands for PET imaging with the primary purpose of measuring the proportion of receptors in the high-affinity (activating) state. Although several lines of research support the presence of high and low-affinity states of D₂Rs and their detection by in vivo imaging paradigms, a growing body of controversial data has now called this into question. These include both in vivo and ex vivo studies of anesthesia effects, rodent models with increased proportions of high-affinity state D₂Rs as well as the molecular evidence for stable receptor–G-protein complexes. In this commentary we review these data and discuss the evidence for the in vivo existence of D₂Rs configured in high and low-affinity states and whether or not the high-affinity state of the D₂R can, in fact, be imaged in vivo with agonist radioligands.

© 2011 Elsevier Inc. Elsevier Inc. All rights reserved.

1. Introduction

Neuroreceptor imaging techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) have been used for more than three decades to image and quantify dopamine D₂ receptors (D₂R) in the primate brain. Neuroreceptor imaging has also been used to assess endogenous dopamine release indirectly by measuring the dopamine displacement of D₂R radioligand binding after a pharmacological challenge with psychostimulants (e.g., amphetamines or methylphenidate). The theoretical justification for this approach to measuring dopamine release in vivo was provided by the classical occupancy model. Briefly, amphetamine-induced release of endogenous dopamine will increase occupancy of the

D₂Rs by dopamine, thereby decreasing the binding potential (BP_{ND}) of the radiotracer, a parameter that is measured in PET imaging and is proportional to the product of receptor density (B_{\max}) and the affinity (1/Kd) of the radiotracer [1]. Several imaging studies have provided support for the occupancy model using benzamide antagonist radioligands and amphetamine challenge. However, even at high doses of amphetamine, D₂R radioligand binding is not reduced beyond ~50%, a phenomenon referred to as the ceiling effect [1–4]. Several explanations have been proposed for this ceiling effect: (1) receptors located extrasynaptically are less accessible to competition from synaptically released dopamine, or maybe there is not enough dopamine to fully displace the radioligand, (2) internalized receptors are inaccessible to dopamine competition but still accessible to the relatively lipophilic radioligand, and/or (3) since D₂Rs are configured in high and low-affinity state for agonist binding, dopamine competes primarily at the high-affinity sites of D₂R but spares the low-affinity sites [1]. Although several lines of research support the presence of high and low-affinity state D₂Rs and their detection by in vivo imaging paradigms, a growing body of evidence has now called this into

* Corresponding author at: Department of Translational Imaging, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 31, New York, NY 10032, USA. Tel.: +1 212 543 6085.

E-mail address: ms4148@columbia.edu (M. Skinbjerg).

question. The purpose of this commentary is to review these data and promote discussion about the existence in vivo of two populations of the D₂R configured in high and low-affinity states for agonist binding, and to address whether a high-affinity state of the D₂R can in fact be imaged with agonist radioligands.

2. The two-state occupancy model

The experimental basis for imaging high-affinity state D₂Rs with agonist radioligands was provided by competition binding assays in washed brain membrane homogenates. These assays demonstrated that agonists bind with both high and low-affinity to the D₂R in the absence of guanine nucleotide triphosphate (GTP), but with low-affinity in the presence of GTP [5–7]. GTP binding to Gα subunit promotes G-protein activation and dissociation from the receptor, resulting in a loss of high-affinity agonist binding. The ternary complex model provided the first description of the mechanistic interactions of agonist-receptor–G-protein (Fig. 1). In this model the receptors exist as G-protein coupled and uncoupled; the G-protein coupled state has a high-affinity for agonist binding whereas the uncoupled form has a low-affinity for agonist [8]. The ternary complex model provided the theoretical framework for the two-state occupancy model for neuroreceptor imaging. The two-state occupancy model predicts that amphetamine challenge would show greater displacement of agonist than of antagonist radioligands by dopamine, and the ceiling effect could be conceptualized as displacement by dopamine only of the fraction of receptors configured in the high-affinity state. A confounding issue with this conceptualization is that cells are not GTP depleted and the ternary complex does not accumulate in vivo as it does in steady state measurements in in vitro membrane preparations. This issue will be discussed further in the section describing the molecular mechanism of agonist binding.

3. PET studies of D₂Rs in the high-affinity state

Since the initial proposal of the two-state occupancy model, multiple studies have aimed at imaging the D₂R in the high-affinity




Fig. 1. The ternary complex model proposes that D₂Rs exist as G-protein coupled and uncoupled, of which the G-protein coupled form reflects a state with high-affinity for agonist binding and the uncoupled form reflects a low affinity state [8].

state with agonist radioligands [9–12]. A review of 13 PET studies reveals inconclusive evidence for the two-state occupancy model (Table 1). Seven studies (all used anesthesia) supported the ability to image high-affinity state D₂Rs with agonist radioligands while six studies (four used anesthesia) failed to support this hypothesis. Consistent with the two-state occupancy model, three novel agonist radioligands [¹¹C]PHNO (4-propyl-9-hydroxynaphthoxazine), [¹¹C]NPA ((–)-N-propyl-norapomorphine) and [¹¹C]MNPA ((R)-2-CH₃O-N-n-propyl-norapomorphine) showed almost two-fold greater displacement after amphetamine challenge than antagonist radioligands in anesthetized animals [13–18]. In contrast, amphetamine challenge did not produce greater displacement of [¹¹C]MNPA or [¹¹C]NPA than of [¹¹C]raclopride in conscious monkey or human, suggesting a confounding effect of anesthesia [17,20]. In line with this, PET studies of anesthetized vs conscious monkeys showed increased [¹¹C]MNPA and decreased

Table 1
PET studies.

Imaging paradigm	Ref	Anesthesia	Radioligand		Species	Favor D2 high
			Agonist	Antagonist		
<i>Challenge</i>						
Amphetamines	Narendran et al. [13]	Isoflurane	[¹¹ C]NPA	[¹¹ C]Raclopride	Monkey	Y
	Hwang et al. [19]	Isoflurane	[¹¹ C]NPA	[¹¹ C]Raclopride	Monkey	Y
	Ginovart et al. [15]	Isoflurane	[¹¹ C]PHNO	[¹¹ C]Raclopride	Cat	Y
	Seneca et al. [16]	Ketamine/xylazine	[¹¹ C]MNPA	[¹¹ C]Raclopride	Monkey	Y
	Ohba et al. [17]	Ketamine/xylazine	[¹¹ C]MNPA		Monkey	Y
	Ohba et al. [17]	Conscious	[¹¹ C]MNPA		Monkey	N
	Skinbjerg et al. [18]	Isoflurane	[¹¹ C]MNPA	[¹⁸ F]Fallypride	Mouse	Y
	Narendran et al. [20]	Conscious	[¹¹ C]NPA	[¹¹ C]Raclopride	Human	N
(+)-PD 128907	Kortekaas et al. [26]	Isoflurane		[¹¹ C]Raclopride	Monkey	N
Apomorphine	Finnema et al. [25]	Ketamine/xylazine	[¹¹ C]MNPA	[¹¹ C]Raclopride	Monkey	N
<i>Scatchard</i>						
Variable specific activity	Narendran et al. [14]	Isoflurane	[¹¹ C]NPA	[¹¹ C]Raclopride	Monkey	Y
	Ginovart et al. [15]	Isoflurane	[¹¹ C]PHNO	[¹¹ C]Raclopride	Cat	N
<i>Animal models of increased D2 high</i>						
Baseline	Skinbjerg et al. [18]	Isoflurane	[¹¹ C]MNPA		Mouse	N
<i>Anesthesia effect</i>						
Baseline	Tsukada et al. [21]	Conscious vs ketamine		[¹¹ C]Raclopride	Monkey	Effect of anesthesia on binding
	Hassoun et al. [24]	Conscious vs ketamine		[¹¹ C]Raclopride	Cat	Decreased
	Hassoun et al. [24]	Conscious vs halothane		[¹¹ C]Raclopride	Cat	No change
	Ohba et al. [17]	Conscious vs ketamine/xylazine	[¹¹ C]MNPA		Monkey	Increase

[^{11}C]raclopride baseline BP_{ND} under anesthetized conditions. Moreover, methamphetamine (1 mg/kg iv) produced a $\sim 44\%$ decrease of [^{11}C]MNPA BP_{ND} in anesthetized monkeys but only $\sim 17\%$ decrease in conscious monkeys, an effect that appeared to be primarily due to the increased baseline BP_{ND} of [^{11}C]MNPA [17,21]. The exact mechanism for the effect of anesthesia on BP_{ND} of agonists and antagonists is unclear but thermodynamic properties of the ligands, shift of high/low-affinity ratio as well as the type of anesthesia have been proposed [17,22–24]. Two other challenge studies used increasing doses of exogenous D_2R agonist to establish an inhibition curve in vivo similar to those obtained with competition assays in vitro [25,26]. Neither study was able to demonstrate the bi-phasic displacement of [^{11}C]raclopride characteristic of the high and low-affinity states observed in in vitro studies. The agonist apomorphine showed similar IC_{50} value for [^{11}C]MNPA and [^{11}C]raclopride, suggesting that the PET radioligands bind to an indistinguishable population of the D_2Rs in vivo [25,26]. In agreement with this, a PET study of a mouse model reported to exhibit increased proportions of high-affinity state D_2Rs failed to find increased baseline BP_{ND} of [^{11}C]MNPA compared to wildtype mice [27–29].

Thus, PET studies have not consistently supported the possibility of imaging high-affinity state D_2Rs with agonists; therefore, the evidence for this is inconclusive.

4. Ex vivo studies of D_2Rs in the high-affinity state

The possibility of measuring high-affinity state D_2Rs with agonist radioligands has also been investigated in a number of ex vivo studies. Briefly, these studies were performed by intravenous administration of radioligands in either conscious or anesthetized rodents. The rodents were euthanized by decapitation at various time points and the radioactivity was measured in the brain tissue. As was the case for the PET investigations, a review of 12 ex vivo studies revealed inconclusive evidence for the two-state occupancy model (Table 2). Seven studies, using striatal tissue from rats that had not received anesthesia, found no difference in the displacement of [^{11}C] or [^3H]PHNO, [^3H]MNPA [^3H]NPA and [^3H]raclopride by amphetamine challenge or exogenously

administered agonists [30–33]. Notably, one of these studies was performed using rat models previously reported to have an increased proportion of D_2R in the high-affinity state measured with competition binding in striatal homogenates [30,34,35]. In contrast, four studies, including one model of increased high-affinity D_2R , did report greater displacement of agonist than antagonist radioligands by amphetamine challenge or exogenously administered agonists in tissue from conscious rodents [36–38]. A recent ex vivo study by McCormick and colleagues investigated the effect of anesthesia on radioligand binding [33]. As was seen for in vivo PET imaging, anesthesia produced a marked increase in baseline binding of agonist radioligands accompanied by a significantly larger displacement by amphetamine than [^3H]raclopride. In contrast, amphetamine challenge produced a similar magnitude of displacement of both agonists and [^3H]raclopride in tissue from conscious rats [33].

In summary, the evidence for high-affinity state D_2Rs in vivo and ex vivo has so far been inconclusive. To explore and discuss potential explanations for this conflicting literature, we will review the molecular basis for high-affinity agonist binding.

5. Molecular mechanisms of agonist binding at the dopamine D_2 receptor

The high and low-affinity states of the D_2R are often referred to as G-protein coupled and uncoupled, respectively. While this makes sense in terms of the ternary complex model and under GTP depleted and stabilized conditions in membrane binding assays, evidence for the existence of pre-coupled complexes in living cells is conflicting. Two different theories have been proposed to explain receptor–G-protein interaction in the absence and presence of agonist (Fig. 2):

- (1) The pre-coupled theory proposes that some receptors form stable complexes with G-proteins. These complexes induce a state of the receptor with high-affinity for agonist binding. Agonist binding induces a conformational change of the receptor that activates the G-protein [39,40].

Table 2
Ex vivo studies.

Study design	Ref	Anesthesia	Radioligand		Species	Favor D2 high
			Agonist	Antagonist		
<i>Challenge</i>						
Amphetamines	Cumming et al. [37,38]	Conscious	[³ H]NPA	[¹¹ C]Raclopride	Mouse	Y
	McCormick et al. [31]	Conscious	[¹¹ C]PHNO	[³ H]Raclopride	Rat	N
	McCormick et al. [33]	Isoflurane	[³ H]PHNO [¹¹ C]PHNO	[³ H]Raclopride	Rat	Y
	McCormick et al. [33]	Conscious	[¹¹ C]NPA [³ H]PHNO [¹¹ C]PHNO	[³ H]Raclopride	Rat	N
Quinagolide	Cumming et al. [37,38]	Conscious	[³ H]NPA	[¹¹ C]Raclopride	Mouse	Y (N) ^a
NPA	McCormick et al. [31]	Conscious	[¹¹ C]PHNO	[³ H]Raclopride	Rat	N
Aripiprazole	McCormick et al. [31]	Conscious	[¹¹ C]PHNO	[³ H]Raclopride	Rat	N
NPA	Seeman [36]	Conscious	[³ H]PHNO	[³ H]Raclopride	Rat	Y
Quinpirole	Peng et al. [32]	Conscious	[³ H]PHNO [³ H]MNPA	[³ H]Raclopride	Rat	N
Aripiprazole	Peng et al. [32]	Conscious	[³ H]PHNO [³ H]MNPA	[³ H]Raclopride	Rat	N
<i>Animal models of increased D2 high</i>						
NPA challenge	Seeman [36]	Conscious	[³ H]PHNO		Rat	Y
Amphetamine challenge (3 rat models)	McCormick et al. [30]	Conscious	[¹¹ C]PHNO	[³ H]Raclopride	Rat	N
<i>Anesthesia effect</i>						
Baseline	McCormick et al. [33]	Conscious vs isoflurane	[³ H]PHNO [¹¹ C]PHNO [¹¹ C]NPA		Rat	Effect of anesthesia on binding Increase
	McCormick et al. [33]	Conscious vs isoflurane		[³ H]Raclopride	Rat	Unchanged

^a Baseline was defined as the dopamine depleted condition. When compared to the saline treated group, quinagolide displaced both ligands to the same extent (Cumming, et al. [37,38]; Finnema et al. [25]).




Fig. 2. (A) The pre-coupled theory proposes that receptors form stable complexes with G-proteins with high-affinity for agonist. (B) The collision theory proposes the receptors and G-proteins diffuse freely within the plasma membrane in the absence of agonist. Upon agonist binding the receptors will couple to and activate the G-proteins [39,40].

- (2) The collision theory proposes that receptors and G-proteins diffuse freely within the plasma membrane in the absence of agonist. Upon agonist binding, the receptor adopts a conformation with a higher affinity for G-protein, which enhances interaction with and subsequent activation of the G-protein [39,40].

These hypotheses have been investigated using resonance energy transfer (RET) techniques, such as Förster/fluorescence (FRET) and bioluminescence (BRET) resonance energy transfer, which allow direct assessment of the interactions between receptor and G-protein. The RET techniques make use of recombinant receptor and G-protein constructs fused with donor and acceptor molecules. By measuring the energy transfer from donor to acceptor, which takes place only when the molecules are in close proximity (≤ 10 nm), the RET techniques can study receptor–G-protein interactions [41,42]. One study interpreted basal FRET signal from receptor and G-protein as evidence for pre-coupling but did not further investigate the interactions [43]. Despite the existence of a basal BRET signal that could be consistent with some pre-coupling of receptor and G-protein, a recent study observed a large enhancement of receptor–G-protein BRET upon addition of agonist, consistent with either recruitment of G-protein to the receptor and/or with an optimized interaction with pre-coupled G-protein [44]. Lambert and colleagues argued against pre-coupling of D₂R and G-protein and showed a marked increase in BRET signal after agonist stimulation, suggesting that agonist stimulation of D₂R promoted G-protein coupling [45]. Moreover, the agonist-stimulated BRET signal was significantly enhanced by depletion of guanine nucleotides, which stabilizes the ternary complex [45]. A recent study of D₁R even suggested that receptor internalization promotes signaling, thus proposing a delayed onset of G-protein activation [46]. Similar studies of other GPCRs have reported conflicting evidence for the pre-coupling vs collision theory, consistent with the idea that the propensity for G-protein pre-coupling may vary for different receptors [43,45,47–50].

It is important to realize that even the absence of pre-coupled D₂R does not exclude high-affinity agonist binding. The affinity of a

ligand is the reciprocal of the equilibrium dissociation constant K_d and dependent on the association and dissociation rate constants (k_{on} and k_{off}):

$$K_d = \frac{k_{off} \text{ min}^{-1}}{k_{on} \text{ M}^{-1} \text{ min}^{-1}}$$

From this we can observe that changes in either of the rate constants will be reflected by a change in affinity. That is, a faster on rate would lead to higher affinity, a faster off rate would lead to lower affinity and vice versa. We know from binding assays in membrane homogenates that high-affinity agonist binding reflects the rate constants from a stabilized ternary complex under guanine nucleotide-depleted conditions. A major difference between the membrane binding assays and PET imaging is that living cells, unlike membranes, contain endogenous GTP and allow G-protein activation. By assuming that agonist binds to a high-affinity state *in vivo* determined solely by pre-coupling to G-proteins, we automatically exclude the impact of G-protein collision, activation and/or dissociation, which can affect both k_{on} and k_{off} in living cells. Competition binding studies in intact cells better reflect the *in vivo* situation. One such study detected a very small fraction of high-affinity binding at D₂R only when using a certain antagonist ([³H] domperidone) [51]. Two other studies were unable to detect high-affinity binding to D₂R, suggesting that stable ternary complex does not accumulate in live cells [52,53]. In line with this, depletion of endogenous GTP in intact cells expressing μ -opioid receptors decreased the k_{off} of the opioid agonist [³H]DAMGO with no change in the k_{on} , resulting in increased affinity of the agonist [54]. Interestingly, intact cell binding studies of β -adrenergic receptors under non-equilibrium conditions have detected short-term (<1 min) high-affinity agonist binding, however, when the binding assays were performed under equilibrium only low-affinity binding was observed [55–57]. Thus, more sophisticated *in vitro* methods are needed to determine how coupling and activation of G-proteins affect the affinity of agonist ligands.

It is important to note that practical experience has shown that PET imaging requires radioligands with nanomolar to sub-nanomolar affinity in order to achieve high signal to noise ratio. In membrane homogenates the K_i values of NPA have been reported to be in the range of 0.1–0.4 nM (average 0.2 nM) for the D_2R high-affinity state and 4.6–26 nM (average 15 nM) for the low-affinity state [5,7,53,58,59]. Similar affinity values have been reported for MNPA, while single K_d/K_i values in the range of 0.2–8.5 nM (average 1.8 nM) have been reported for PHNO, which is more selective for the D_3R receptors in vivo [53,58,60–63]. Given these values, D_2R agonists would be expected to bind exclusively to the high-affinity state in order to achieve a measurable signal under tracer conditions. A recent review of multiple D_2R ligands, reported that their apparent affinity generally was about 10 fold lower in vivo than the in vitro measurements [64]. For example, measurements of the apparent K_d of raclopride in vivo range from 1.6 to 12 nM (average 9.1 nM at baseline) compared to 0.8–2.5 nM (average 1.2 nM) in vitro [64]. However most of the in vivo studies did not correct for factors such as free fraction in brain tissue and concentration of endogenous dopamine, which affect the accuracy of in vivo estimates of apparent affinities [14,64,65]. D_2R radioligands also bind with high affinity to the D_3R , and in particular PHNO has been shown to be D_3 -preferring in vivo. Therefore, the contribution of D_3R binding to BP_{ND} differs among the ligands and may interfere with direct comparisons of agonist vs antagonist ligands [63,66]. As the D_3R is expressed at lower density and in more restricted regions (i.e. ventral striatum and globus pallidus) than the D_2R , this confound might be overcome by avoiding D_3R rich regions and/or by development of radioligands with higher D_2R selectivity.

In summary, more studies are needed to establish whether D_2R s (and other GPCRs) are stably configured in high and low-affinity states in vivo and whether the high-affinity state can be measured with agonist radioligands. Possible approaches include the use of genetically modified mice expressing a D_2R incapable of G-protein coupling. It is possible however, that high and low-affinity agonist binding may be undetectable in vivo, given the dynamic alterations in receptor conformation that are associated with binding and unbinding of both ligand and G-protein [67–71]. Considering that the affinity measure is an average of numerous events per unit time, distinguishing between two populations of high and low-affinity state receptors is a simplification that perhaps does not capture the subtlety of the actual phenomenon. It is conceivable that imaging approaches to detect GPCR activation in vivo will become available and thereby provide alternative ways to measure the function of GPCRs, G-protein activation and signal transduction. In addition, new approaches using single molecule imaging may ultimately uncover the behavior of receptors at the level of an individual receptor, thereby avoiding the confounds of time and event averaged data.

Acknowledgements

The authors thank Mark Slifstein for fruitful discussions and feedback.

References

- [1] Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. *J Cereb Blood Flow Metab* 2000;20:423–51.
- [2] Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. *Proc Natl Acad Sci USA* 1997;94:2569–74.
- [3] Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, et al. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. *Synapse* 1997;25:1–14.
- [4] Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N. Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [^{11}C]raclopride? PET studies combined with microdialysis in conscious monkeys. *Brain Res* 1999;841:160–9.
- [5] De Lean A, Kilpatrick BF, Caron MG. Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists. *Mol Pharmacol* 1982;22:290–7.
- [6] McDonald WM, Sibley DR, Kilpatrick BF, Caron MG. Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D_2 dopamine receptors. *Mol Cell Endocrinol* 1984;36:201–9.
- [7] Sibley DR, De Lean A, Creese I. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D_2 dopamine receptor. *J Biol Chem* 1982;257:6351–61.
- [8] De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. *J Biol Chem* 1980;255:7108–17.
- [9] Hwang DR, Kegeles LS, Laruelle M. (–)-N-[(11C)]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of $D(2)$ receptors. *Nucl Med Biol* 2000;27:533–9.
- [10] Gao YG, Baldessarini RJ, Kula NS, Neumeyer JL. Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues. *J Med Chem* 1990;33:1800–5.
- [11] Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, et al. Radiosynthesis and evaluation of [^{11}C](+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D_2 high-affinity state with positron emission tomography. *J Med Chem* 2005;48:4153–60.
- [12] Finnema SJ, Seneca N, Farde L, Shchukin E, Sovago J, Gulyas B, et al. A preliminary PET evaluation of the new dopamine D_2 receptor agonist [^{11}C]MNPA in cynomolgus monkey. *Nucl Med Biol* 2005;32:353–60.
- [13] Narendran R, Hwang DR, Slifstein M, Talbot PS, Erritzoe D, Huang Y, et al. In vivo vulnerability to competition by endogenous dopamine: comparison of the D_2 receptor agonist radiotracer (–)-N-[(11C)]propyl-norapomorphine ([^{11}C]NPA) with the D_2 receptor antagonist radiotracer [^{11}C]raclopride. *Synapse* 2004;52:188–208.
- [14] Narendran R, Hwang DR, Slifstein M, Hwang Y, Huang Y, Ekelund J, et al. Measurement of the proportion of D_2 receptors configured in state of high affinity for agonists in vivo: a positron emission tomography study using [^{11}C]N-propyl-norapomorphine and [^{11}C]raclopride in baboons. *J Pharmacol Exp Ther* 2005;315:80–90.
- [15] Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, et al. Binding characteristics and sensitivity to endogenous dopamine of [^{11}C](+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D_2 receptors in vivo using positron emission tomography. *J Neurochem* 2006;97:1089–103.
- [16] Seneca N, Finnema SJ, Farde L, Gulyas B, Wikstrom HV, Halldin C, et al. Effect of amphetamine on dopamine D_2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [^{11}C]MNPA and antagonist [^{11}C]raclopride. *Synapse* 2006;59:260–9.
- [17] Ohba H, Harada N, Nishiyama S, Kakiuchi T, Tsukada H. Ketamine/xylazine anesthesia alters [^{11}C]MNPA binding to dopamine D_2 receptors and response to methamphetamine challenge in monkey brain. *Synapse* 2009;63:534–7.
- [18] Skinbjerg M, Liow JS, Seneca N, Hong J, Lu S, Thorsell A, et al. D_2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model. *Neuroimage* 2010;50:1402–7.
- [19] Hwang DR, Narendran R, Laruelle M. Positron-labeled dopamine agonists for probing the high affinity states of dopamine subtype 2 receptors. *Bioconjug Chem* 2005;16:27–31.
- [20] Narendran R, Mason NS, Laymon CM, Lopresti BJ, Velasquez ND, May MA, et al. A comparative evaluation of the dopamine $D(2/3)$ agonist radiotracer [^{11}C](–)-N-propyl-norapomorphine and antagonist [^{11}C]raclopride to measure amphetamine-induced dopamine release in the human striatum. *J Pharmacol Exp Ther* 2010;333:533–9.
- [21] Tsukada H, Harada N, Nishiyama S, Ohba H, Sato K, Fukumoto D, et al. Ketamine decreased striatal [(11C)]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis. *Synapse* 2000;37:95–103.
- [22] Kilpatrick GJ, el Tayar N, Van de Waterbeemd H, Jenner P, Testa B, Marsden CD. The thermodynamics of agonist and antagonist binding to dopamine D_2 receptors. *Mol Pharmacol* 1986;30:226–34.
- [23] Agui T, Amlaiki N, Caron MG, Keabian JW. Binding of [125I]-N-(p-aminophenethyl)spiroperidol to the D_2 -dopamine receptor in the neurointermediate lobe of the rat pituitary gland: a thermodynamic study. *Mol Pharmacol* 1988;33:163–9.
- [24] Hassoun W, Le Cavorsin M, Ginovart N, Zimmer L, Gualda V, Bonnefoi F, et al. PET study of the [^{11}C]raclopride binding in the striatum of the awake cat: effects of anaesthetics and role of cerebral blood flow. *Eur J Nucl Med Mol Imaging* 2003;30:141–8.
- [25] Finnema SJ, Halldin C, Bang-Andersen B, Gulyas B, Bundgaard C, Wikstrom HV, et al. Dopamine $D(2/3)$ receptor occupancy of apomorphine in the nonhuman primate brain-A comparative PET study with [^{11}C]raclopride and [^{11}C]MNPA. *Synapse* 2009;63:378–89.
- [26] Kortekaas R, Maguire RP, Cremers TI, Dijkstra D, van Waarde A, Leenders KL. In vivo binding behavior of dopamine receptor agonist (+)-PD 128907 and

- implications for the ceiling effect in endogenous competition studies with [^{11}C]raclopride – a positron emission tomography study in Macaca mulatta. *J Cereb Blood Flow Metab* 2004;24:531–5.
- [27] Skinbjerg M, Seneca N, Liow JS, Hong J, Weinshenker D, Pike VW, et al. Dopamine beta-hydroxylase-deficient mice have normal densities of D(2) dopamine receptors in the high affinity state based on in vivo PET imaging and in vitro radioligand binding. *Synapse* 2010.
 - [28] Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, et al. Dopamine supersensitivity correlates with D₂High states, implying many paths to psychosis. *Proc Natl Acad Sci USA* 2005;102:3513–8.
 - [29] Schank JR, Ventura R, Puglisi-Allegra S, Alcaro A, Cole CD, Liles LC, et al. Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. *Neuropsychopharmacology* 2006;31:2221–30.
 - [30] McCormick PN, Kapur S, Reckless G, Wilson AA. Ex vivo [^{11}C](+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D₂ receptor in vitro. *Synapse* 2009;63:998–1009.
 - [31] McCormick PN, Kapur S, Seeman P, Wilson AA. Dopamine D2 receptor radiotracers [^{11}C](+)-PHNO and [^3H]raclopride are indistinguishably inhibited by D₂ agonists and antagonists ex vivo. *Nucl Med Biol* 2008;35:11–7.
 - [32] Peng T, Zysk J, Dorff P, Elmore CS, Strom P, Malmquist J, et al. D2 receptor occupancy in conscious rat brain is not significantly distinguished with [(3)H]-MNPA, [(3)H]-(+)-PHNO, and [(3)H]-raclopride. *Synapse* 2010;64:624–33.
 - [33] McCormick PN, Ginovart N, Wilson AA. Isoflurane anaesthesia differentially affects the amphetamine sensitivity of agonist and antagonist D2/D3 positron emission tomography radiotracers: implications for in vivo imaging of dopamine release. *Mol Imaging Biol* 2011;13:737–46.
 - [34] Seeman P, Tallerico T, Ko F, Tenn C, Kapur S. Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. *Synapse* 2002;46:235–9.
 - [35] Seeman P, Tallerico T, Ko F. Alcohol-withdrawn animals have a prolonged increase in dopamine D2high receptors, reversed by general anesthesia: relation to relapse? *Synapse* 2004;52:77–83.
 - [36] Seeman P. Dopamine D2High receptors measured ex vivo are elevated in amphetamine-sensitized animals. *Synapse* 2009;63:186–92.
 - [37] Cumming P, Wong DF, Dannals RF, Gillings N, Hilton J, Scheffel U, et al. The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. *Ann NY Acad Sci* 2002;965:440–50.
 - [38] Cumming P, Wong DF, Gillings N, Hilton J, Scheffel U, Gjedde A. Specific binding of [^{11}C]raclopride and N-[^3H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein. *J Cereb Blood Flow Metab* 2002;22:596–604.
 - [39] Hein P, Frank M, Hoffmann C, Lohse MJ, Bunemann M. Dynamics of receptor/G protein coupling in living cells. *EMBO J* 2005;24:4106–14.
 - [40] Hein P, Bunemann M. Coupling mode of receptors and G proteins. *Naunyn Schmiedeberg Arch Pharmacol* 2009;379:435–43.
 - [41] Xu Y, Piston DW, Johnson CH. A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins. *Proc Natl Acad Sci USA* 1999;96:151–6.
 - [42] Wang Y, Wang N. FRET and mechanobiology. *Integr Biol (Camb)* 2009;1:565–73.
 - [43] Nobles M, Benians A, Tinker A. Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells. *Proc Natl Acad Sci USA* 2005;102:18706–11.
 - [44] Urizar E, Yano H, Kolster R, Gales C, Lambert N, Javitch JA. CODA-RET reveals functional selectivity as a result of GPCR heteromerization. *Nat Chem Biol* 2011;7:624–30.
 - [45] Kuravi S, Lan TH, Barik A, Lambert NA. Third-party bioluminescence resonance energy transfer indicates constitutive association of membrane proteins: application to class a g-protein-coupled receptors and g-proteins. *Biophys J* 2010;98:2391–9.
 - [46] Kotowski SJ, Hopf FW, Seif T, Bonci A, von Zastrow M. Endocytosis promotes rapid dopaminergic signaling. *Neuron* 2011;71:278–90.
 - [47] Gales C, Van Durm JJ, Schaak S, Pontier S, Percherancier Y, Audet M, et al. Probing the activation-promoted structural rearrangements in preassembled receptor–G protein complexes. *Nat Struct Mol Biol* 2006;13:778–86.
 - [48] Gales C, Rebois RV, Hogue M, Trieu P, Breit A, Hebert TE, et al. Real-time monitoring of receptor and G-protein interactions in living cells. *Nat Methods* 2005;2:177–84.
 - [49] Qin K, Sethi PR, Lambert NA. Abundance and stability of complexes containing inactive G protein-coupled receptors and G proteins. *FASEB J* 2008;22:2920–7.
 - [50] Audet N, Gales C, Archer-Lahlou E, Vallieres M, Schiller PW, Bouvier M, et al. Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins. *J Biol Chem* 2008;283:15078–8.
 - [51] Seeman P. Dopamine D2(High) receptors on intact cells. *Synapse* 2008;62:314–8.
 - [52] Sibley DR, Mahan LC, Creese I. Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. *Mol Pharmacol* 1983;23:295–302.
 - [53] Skinbjerg M, Namkung Y, Halldin C, Innis RB, Sibley DR. Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors. *Synapse* 2009;63:462–75.
 - [54] Yabaluri N, Medzihradsky F. Reversible modulation of opioid receptor binding in intact neural cells by endogenous guanosine triphosphate. *Mol Pharmacol* 1995;48:690–5.
 - [55] Toews ML, Harden TK, Perkins JP. High-affinity binding of agonists to beta-adrenergic receptors on intact cells. *Proc Natl Acad Sci USA* 1983;80:3553–7.
 - [56] Toews ML, Perkins JP. Agonist-induced changes in beta-adrenergic receptors on intact cells. *J Biol Chem* 1984;259:2227–35.
 - [57] Zhu SJ, Toews ML. Intact cell binding properties of cells expressing altered beta-adrenergic receptors. *Mol Pharmacol* 1994;45:255–61.
 - [58] Kara E, Lin H, Strange PG. Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics. *J Neurochem* 2010;112:1442–53.
 - [59] Gardner B, Strange PG. Agonist action at D2(long) dopamine receptors: ligand binding and functional assays. *Br J Pharmacol* 1998;124:978–84.
 - [60] Seeman P, Ulpian C, Larsen RD, Anderson PS. Dopamine receptors labelled by PHNO. *Synapse* 1993;14:254–62.
 - [61] Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, et al. Expression and pharmacological characterization of the human D₃ dopamine receptor. *J Pharmacol Exp Ther* 1994;268:417–26.
 - [62] Vasdev N, Seeman P, Garcia A, Stableford WT, Nobrega JN, Houle S, et al. Syntheses and in vitro evaluation of fluorinated naphthoxazines as dopamine D₂/D₃ receptor agonists: radiosynthesis, ex vivo biodistribution and autoradiography of [^{18}F]F-PHNO. *Nucl Med Biol* 2007;34:195–203.
 - [63] Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E, et al. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [^{11}C](+)-PHNO is a D3 receptor preferring agonist in vivo. *Synapse* 2006;60:485–95.
 - [64] Cumming P. Absolute abundances and affinity states of dopamine receptors in mammalian brain: a review. *Synapse* 2011;65:892–909.
 - [65] Laruelle M, al-Tikriti MS, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, et al. In vivo quantification of dopamine D2 receptor parameters in nonhuman primates with [^{123}I]iodobenzofuran and single photon emission computerized tomography. *Eur J Pharmacol* 1994;263:39–51.
 - [66] Seneca N, Zoghbi SS, Skinbjerg M, Liow JS, Hong J, Sibley DR, et al. Occupancy of dopamine D₂₍₃₎ receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [^{11}C]MNPA. *Synapse* 2008;62:756–63.
 - [67] Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model. III. Resurrecting efficacy. *J Theor Biol* 1996;181:381–97.
 - [68] Gether U, Kobilka BK. G protein-coupled receptors. II. Mechanism of agonist activation. *J Biol Chem* 1998;273:17979–82.
 - [69] Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. *Endocr Rev* 2000;21:90–113.
 - [70] Strange PG. G-protein coupled receptors: conformations and states. *Biochem Pharmacol* 1999;58:1081–8.
 - [71] Lefkowitz RJ, Cotecchia S, Samama P, Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. *Trends Pharmacol Sci* 1993;14:303–7.